REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO will join Baird and Morgan Stanley healthcare conferences, offering webcast access and 30-day replays for investors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (RGNX) will participate in two upcoming healthcare investor conferences in New York in September 2026.
The company is scheduled for fireside chats at the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, and at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Live webcasts of select events will be accessible through the Investors section of REGENXBIO's website, with archived replays available for about 30 days after the events.
Details
News Market Reaction – RGNX
On Sep 8, the day this news came out, RGNX closed 2.01% below the previous close.
Data tracked by StockTitan Argus for the Sep 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Baird 2026 Global Healthcare Conference
Fireside Chat: Tuesday, September 15 at 8:30 a.m. ET
Location:
Morgan Stanley 24th Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 16 at 8:30 a.m. ET
Location:
Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302870539.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can investors access REGENXBIO's presentations at the upcoming conferences?
Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will remain available for approximately 30 days following the events.